Nanomedicines for ocular NSAIDs: safety on drug delivery

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 4, 2009, Pages 394-401

  Araújo, Joana ^a   Gonzalez, Elisabet ^a   Egea, Maria Antonia ^a   Garcia, Marisa Luisa ^a   Souto, Eliana B ^b,c  

^a CATALAN INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY ICN2   (Spain)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Lipid nanoparticles; Liposomes; Microemulsions; Nanomedicines; Nonsteroidal anti inflammatory drugs; Ocular therapy; Polymeric nanoparticles

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CONTROLLED RELEASE; DELIVERY SYSTEMS; DOSAGE FORMS; DRUG PENETRATION; DRUG PERMEATION; EPITHELIAL MEMBRANES; EYE TISSUES; HIGH EFFICIENCY; INFLAMMATORY RESPONSE; LIPID NANOPARTICLES; LOSS FACTOR; NANOMEDICINES; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; OCULAR TISSUE; OPHTHALMIC SURGERY; POLYMERIC NANOPARTICLES; RESIDENCE TIME; SIDE EFFECT; SOLID LIPID NANOPARTICLES; THERAPEUTIC LEVELS; TOPICAL FORMULATIONS;

BIOCHEMISTRY; CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; DRUG PRODUCTS; HISTOLOGY; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICROEMULSIONS; NANOCRYSTALS; NANOPARTICLES; PHOSPHOLIPIDS; POLYMERS; SURGERY;

DRUG DOSAGE;

BROMFENAC; CINNARIZINE; DEXAMETHASONE; DICLOFENAC; EUDRAGIT; EYE DROPS; FLURBIPROFEN; GLUCOCORTICOID; GRISEOFULVIN; INDOMETACIN; ITRACONAZOLE; KETOROLAC; LIPOSOME; LOVIRIDE; MEBENDAZOLE; NANOCRYSTAL; NANOSPHERE; NAPROXEN; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PHENYTOIN; PILOCARPINE; PIROXICAM; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; SOLID LIPID NANOPARTICLE; STEROID; UNINDEXED DRUG;

ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; EYE INFLAMMATION; EYE PAIN; EYE SURGERY; EYE TOXICITY; HUMAN; MICROEMULSION; MIOSIS; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATIENT SAFETY; POSTOPERATIVE INFLAMMATION; RETINA MACULA CYSTOID EDEMA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DEATH; DRUG DELIVERY SYSTEMS; EYE; HUMANS; NANOMEDICINE;

EID: 70749161866     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.02.003     Document Type: Article

References (72)

1. Bu H.Z., Gukasyan H.J., Goulet L., Lou X.J., Xiang C., and Koudriakova T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 8 (2007) 91-107
2. Lang J.C. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 16 (1995) 39-43
3. Kaur I.P., Garg A., Singla A.K., and Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 269 (2004) 1-14
4. Bourlais C.L., Acar L., Zia H., Sado P.A., Needham T., and Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 17 (1998) 33-58
5. Romanelli L., Valeri P., Morrone L.A., Pimpinella G., Graziani G., and Tita B. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles. Life Sci 54 (1994) 877-885
6. Loftssona T., and Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 36 (1999) 59-79
7. Kaur I.P., and Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm 28 (2002) 473-493
8. Ding S. Recent development in ophthalmic drug delivery. Pharm Sci Tech Today 1 (1998) 328-335
9. Kayser O., Lemke A., and Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 6 (2005) 3-5
10. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 (2002) 631-651
11. Srinivasan B.D., and Kulkarni P.S. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog Clin Biol Res 312 (1989) 229-249
12. Bhattacherjee P. The role of arachidonate metabolites in ocular inflammation. Prog Clin Biol Res 312 (1989) 211-227
13. Flach A.J. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 36 (1992) 259-284
14. Heier J.S., Topping T.M., Baumann W., Dirks M.S., and Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 107 (2000) 2034-2039
15. O'Brien T.P. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 21 (2005) 1131-1137
16. Flach A.J. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 42 (2002) 1-11
17. Miyake K., Masuda K., Shirato S., Oshika T., Eguchi K., Hoshi H., et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 44 (2000) 58-67
18. Price M.O., and Price F.W. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 20 (2004) 2015-2019
19. Walters T., Raizman M., Ernest P., Gayton J., and Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg 33 (2007) 1539-1545
20. Gamache D.A., Graff G., Brady M.T., Spellman J.M., and Yanni J.M. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24 (2000) 357-370
21. Mainardes R.M., and Silva L.P. Drug delivery systems: past, present, and future. Curr Drug Targets 5 (2004) 449-455
22. Ticho U., Blumenthal M., Zonis S., Gal A., Blank I., and Mazor Z.W. A clinical trial with Piloplex-a new long-acting pilocarpine compound: preliminary report. Ann Ophthalmol 11 (1979) 555-561
23. Giordano G.G., Chevez-Barrios P., Refojo M.F., and Garcia C.A. Biodegradation and tissue reaction to intravitreous biodegradable poly(d,l-lactic-co-glycolic)acid microspheres. Curr Eye Res 14 (1995) 761-768
24. Giannavola C., Bucolo C., Maltese A., Paolino D., Vandelli M.A., Puglisi G., et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 20 (2003) 584-590
25. Das S.K., Tucker I.G., Hill D.J., and Ganguly N. Evaluation of poly(isobutylcyanoacrylate) nanoparticles for mucoadhesive ocular drug delivery. I. Effect of formulation variables on physicochemical characteristics of nanoparticles. Pharm Res 12 (1995) 534-540
26. Vega E., Egea M.A., Valls O., Espina M., and Garcia M.L. Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci 95 (2006) 2393-2405
27. Losa C., Marchal-Heussler L., Orallo F., Vila Jato J.L., and Alonso M.J. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 10 (1993) 80-87
28. Alonso M.J., and Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol 55 (2003) 1451-1463
29. Vandervoort J., and Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 57 (2004) 251-261
30. Irache J.M., Merodio M., Arnedo A., Camapanero M.A., Mirshahi M., and Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 5 (2005) 293-305
31. Calvo P., Vila-Jato J.L., and Alonso M.J. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 85 (1996) 530-536
32. Pignatello R., Bucolo C., and Puglisi G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 91 (2002) 2636-2641
33. Pignatello R., Bucolo C., Ferrara P., Maltese A., Puleo A., and Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16 (2002) 53-61
34. Pignatello R., Bucolo C., Spedalieri G., Maltese A., and Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23 (2002) 3247-3255
35. Adibkia K., Siahi Shadbad M.R., Nokhodchi A., Javadzedeh A., Barzegar-Jalali M., Barar J., et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 15 (2007) 407-416
36. Gomez-Gaete C., Tsapis N., Besnard M., Bochot A., and Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 331 (2007) 153-159
37. Valero J., Egea M.A., Espina M., Gamisans F., and Garcia M.L. Effect of polymerization coadjuvants on nancapsule elaboration and triamcinolone entrapment. Drug Dev Ind Pharm 22 (1996) 167-173
38. Badawi A.A., El-Laithy H.M., El Qidra R.K., El Mofty H., and El Dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 31 (2008) 1040-1049
39. Kreilgaard M. Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. Pharm Res 18 (2001) 367-373
40. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 54 Suppl 1 (2002) S77-S98
41. Gaudana R., Jwala J., Boddu S.H., and Mitra A.K. Recent perspectives in ocular drug delivery. Pharm Res 26 (2009) 1197-1216
42. Patravale V.B., Date A.A., and Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56 (2004) 827-840
43. Warisnoicharoen W., Lansley A.B., and Lawrence M.J. Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour. Int J Pharm 198 (2000) 7-27
44. Chan J., Maghraby G.M., Craig J.P., and Alany R.G. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 328 (2007) 65-71
45. Lv F.F., Zheng L.Q., and Tung C.H. Phase behavior of the microemulsions and the stability of the chloramphenicol in the microemulsion-based ocular drug delivery system. Int J Pharm 301 (2005) 237-246
46. Baydoun L., Furrer P., Gurny R., and Muller-Goymann C.C. New surface-active polymers for ophthalmic formulations: evaluation of ocular tolerance. Eur J Pharm Biopharm 58 (2004) 169-175
47. Klang S., Abdulrazik M., and Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 5 (2000) 521-532
48. Fialho S.L., and da Silva-Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Exp Ophthalmol 32 (2004) 626-632
49. Diebold Y., Jarrin M., Saez V., Carvalho E.L., Orea M., Calonge M., et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials. 28 (2007) 1553-1564
50. Zimmer A., Mutschler E., Lambrecht G., Mayer D., and Kreuter J. Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery system. Pharm Res 11 (1994) 1435-1442
51. Al-Muhammed J., Ozer A.Y., Ercan M.T., and Hincal A.A. In-vivo studies on dexamethasone sodium phosphate liposomes. J Microencapsul 13 (1996) 293-306
52. Muller R.H., Mader K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50 (2000) 161-177
53. Muller R.H., Petersen R.D., Hommoss A., and Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59 (2007) 522-530
54. Muller R.H., Radtke M., and Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54 Suppl 1 (2002) S131-S155
55. Souto E.B., Mehnert W., and Muller R.H. Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23 (2006) 417-433
56. Souto E.B., and Muller R.H. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 23 (2006) 377-388
57. Attama A.A., Schicke B.C., and Muller-Goymann C.C. Further characterization of theobroma oil-beeswax admixtures as lipid matrices for improved drug delivery systems. Eur J Pharm Biopharm 64 (2006) 294-306
58. Attama A.A., Reichl S., and Muller-Goymann C.C. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 355 (2008) 307-313
59. Keck C.M., and Muller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62 (2006) 3-16
60. Trotta M., Gallarate M., Pattarino F., and Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release 76 (2001) 119-128
61. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18 (2003) 113-120
62. Muller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47 (2001) 3-19
63. Kipp J.E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284 (2004) 109-122
64. Van Eerdenbrugh B., Froyen L., Van Humbeeck J., Martens J.A., Augustijns P., and Van den Mooter G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 35 (2008) 127-135
65. Joseph T.M. A critical look at ocular allergy drugs. Am Fam Physician 53 (1996) 2637-2642
66. Sitenga G.L., Ing E.B., Van Dellen R.G., Younge B.R., and Leavitt J.A. Asthma caused by topical application of ketorolac. Ophthalmology 103 (1996) 890-892
67. Stroobants A., Fabre K., and Maudgal P.C. Effect of non-steroidal anti-inflammatory drugs (NSAID) on the rabbit corneal epithelium studied by scanning electron microscopy. Bull Soc Belge Ophtalmol 276 (2000) 73-81
68. Valls R., Vega E., Garcia M.L., Egea M.A., and Valls O.J. Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drug delivery systems. The Open Med Chem J 2 (2008) 66-71
69. Suri S.S., Fenniri H., and Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2 (2007) 16
70. Kay J.H., and Calandra J.K. Interpretation of eye irritation test. J Soc Cosm Chem 13 (1962) 281-289
71. Agnihotri S.M., and Vavia P.R. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 5 (2009) 90-95
72. Bucolo C., Maltese A., Puglisi G., and Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res 34 (2002) 319-323